| Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. | |
| | |
MedLine Citation:
|
PMID: 21554150 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In the last couple of years, the number of patients with chronic inflammatory rheumatic diseases being treated with TNF α antagonist has increased dramatically. Adalimumab, a fully human monoclonal antibody against TNF α, is one of the most frequently administered TNF α antagonists. Yet, unresolved issues are the long-term safety of TNF α antagonists and high treatment costs. AREAS COVERED: The authors summarize the available data on short- and long-term efficacy and safety of adalimumab in the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. The reader will find a comprehensive overview on the safety and efficacy of adalimumab for these conditions. Clinically relevant questions of adalimumab therapy are discussed. A special focus of this review is on the safety of adalimumab therapy. EXPERT OPINION: Adalimumab is effective and reasonably safe in the short- and long-term treatment of patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis who do not respond to the standard therapy. It inhibits radiographic progression in rheumatoid and psoriatic arthritis. Treatment with a TNF α inhibitor such as adalimumab is associated with high treatment costs. |
| | |
Authors:
|
Denis Poddubnyy; Martin Rudwaleit |
Publication Detail:
|
Type: Journal Article; Review Date: 2011-05-10 |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: 10 ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-06-13 Completed Date: 2012-05-07 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 655-73 Citation Subset: IM |
Affiliation:
|
Charite - Campus Benjamin Franklin, Department of Rheumatology , Hindenburgdamm 30, 12203 Berlin , Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal, Humanized / adverse effects, metabolism, therapeutic use* Arthritis, Psoriatic / drug therapy*, metabolism, radiography Arthritis, Rheumatoid / drug therapy*, metabolism, radiography Clinical Trials as Topic / methods Drug Toxicity / chemically induced, metabolism Humans Spondylitis, Ankylosing / drug therapy*, metabolism, radiography Treatment Outcome Tumor Necrosis Factor-alpha / antagonists & inhibitors, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; 0/adalimumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Challenges in assessing regional distribution of inhaled drug in the human lungs.
Next Document: Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma.